Traws Pharma Receives FDA Guidance on Flu Treatment

Traws Pharma ( (TRAW) ) has issued an update.

On May 27, 2025, Traws Pharma announced receiving guidance from the FDA regarding its investigational bird flu and seasonal flu product candidate, tivoxavir marboxil, and plans for stockpiling for pandemic preparedness. This development highlights Traws Pharma’s strategic focus on addressing critical viral threats and enhancing its market positioning by potentially offering first-in-class and best-in-class antiviral therapies, which could significantly impact stakeholders by providing advanced treatment options for pandemic preparedness.

The most recent analyst rating on (TRAW) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.

Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma, Inc. operates in the pharmaceutical industry, focusing on the development of small molecule antiviral drugs targeting respiratory viruses with pandemic potential. The company is working on investigational products like tivoxavir marboxil for bird flu and seasonal flu, and ratutrelvir for COVID-19, aiming to build strategic stockpiles and replace existing therapies.

Average Trading Volume: 119,573

Technical Sentiment Signal: Sell

Current Market Cap: $7.29M

See more insights into TRAW stock on TipRanks’ Stock Analysis page.